Publications by authors named "Tania Gendron"

Article Synopsis
  • The study investigates the role of the genetic variant rs1990622 as a potential modifier of disease risk in frontotemporal lobar degeneration (FTLD), particularly among those with pathogenic variants.
  • Researchers enrolled participants from the ALLFTD study, analyzing the impact of rs1990622 on gray matter volume and cognitive function across various genetic groups related to FTD.
  • Results indicate that carriers of the minor allele of rs1990622 show increased gray matter volume and better cognitive performance, especially in the thalamus and among presymptomatic individuals.
View Article and Find Full Text PDF

We present a longitudinal description of a man with the I383V variant of frontotemporal dementia (FTD). His progressive changes in behavior and language resulted in a diagnosis of the right temporal variant of FTD, also called the semantic behavioral variant (sbvFTD). We also present data from a small series of patients with the I383V variant who were enrolled in a nationwide FTD research collaboration (ALLFTD).

View Article and Find Full Text PDF

The most prominent genetic cause of both amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) is a repeat expansion in the gene C9orf72. Importantly, the transcriptomic consequences of the C9orf72 repeat expansion remain largely unclear. Here, we used short-read RNA sequencing (RNAseq) to profile the cerebellar transcriptome, detecting alterations in patients with a C9orf72 repeat expansion.

View Article and Find Full Text PDF

Inclusions containing TAR DNA binding protein 43 (TDP-43) are a pathological hallmark of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). One of the disease-specific features of TDP-43 inclusions is the aberrant phosphorylation of TDP-43 at serines 409/410 (pS409/410). Here, we developed rabbit monoclonal antibodies (mAbs) that specifically detect pS409/410-TDP-43 in multiple model systems and FTD/ALS patient samples.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the effect of a specific genetic modifier on gray matter volume and cognitive function in patients with Frontotemporal Lobar Degeneration (FTLD), including both mutation carriers and sporadic cases.
  • Participants were recruited from the ALLFTD study and were genotyped for the rs1990622 SNP to assess the relationship between this genetic variant and cognitive outcomes across different genetic groups.
  • Findings indicate that the minor allele of rs1990622 is associated with increased gray matter volume and better cognitive scores in mutation carriers, especially affecting the thalamus, suggesting it may play a role in modifying the risk and impact of FTLD.
View Article and Find Full Text PDF
Article Synopsis
  • Apilimod dimesylate is a new drug targeting phosphoinositide kinase that has shown promise in treating ALS, particularly in models related to C9orf72 and TDP-43.
  • The clinical trial involved 15 participants who were given either apilimod or a placebo for 12 weeks, with a focus on safety and biomarker modulation.
  • Results indicated good safety (no serious side effects) and significant improvements in biomarker levels, suggesting that apilimod dimesylate can effectively engage its intended targets in the CNS.
View Article and Find Full Text PDF
Article Synopsis
  • The letter discusses how new types of cryptic proteins produced by TDP-43 dysfunction could indicate TDP-43-related issues in neurodegenerative diseases.
  • It highlights the significance of these novel proteins as potential biomarkers for diagnosing or understanding these diseases.
  • The findings could lead to improved methods for detecting and studying conditions linked to TDP-43 pathology, such as ALS and frontotemporal dementia.
View Article and Find Full Text PDF

The aggregation, mislocalization, and phosphorylation of TDP-43 are pathologic hallmarks of several neurodegenerative diseases and provide a defining criterion for the neuropathologic diagnosis of Limbic-predominant Age-related TDP-43 Encephalopathy (LATE). LATE neuropathologic changes (LATE-NC) are often comorbid with other neurodegenerative pathologies including Alzheimer's disease neuropathologic changes (ADNC). We examined whether TDP-43 regulated cryptic exons accumulate in the hippocampus of neuropathologically confirmed LATE-NC cases.

View Article and Find Full Text PDF
Article Synopsis
  • Amyotrophic lateral sclerosis (ALS) is a serious neurodegenerative disease that results in the loss of motor neurons, leading to a limited life expectancy of 2 to 5 years after diagnosis.
  • There are currently three FDA-approved drugs that can slow the progression of ALS, but no cure exists, highlighting the urgent need for better biomarkers to improve patient care and accelerate treatment development.
  • The review discusses progress made over the past 20 years in identifying various biomarkers related to diagnosis, prognosis, and treatment response, as well as new strategies being explored for ALS biomarker discovery.
View Article and Find Full Text PDF
Article Synopsis
  • A nucleotide repeat expansion (NRE) in the gene's first intron is linked to the most common genetic causes of ALS and FTD.
  • Researchers discovered that C9 NRE-containing RNAs can undergo exonization and are exported from the nucleus as various spliced mRNA forms, with increased aberrant splicing observed in affected motor neurons and brain tissues.
  • The findings suggest that NREs can trigger abnormal splicing, impacting the production and translation of RNAs, indicating a significant role in these neurodegenerative diseases.
View Article and Find Full Text PDF

Amyotrophic lateral sclerosis (ALS), a devastating motor neuron disease involving complex genetic and environmental factors, is associated with neuroinflammation. Preclinical and clinical studies support immune system involvement in ALS pathogenesis, thereby spurring investigations into potential pathogenic mechanisms, immune response biomarkers, and ALS therapeutics.

View Article and Find Full Text PDF

A summit held March 2023 in Scottsdale, Arizona (USA) focused on the intronic hexanucleotide expansion in the C9ORF72 gene and its relevance in frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS; C9ORF72-FTD/ALS). The goal of this summit was to connect basic scientists, clinical researchers, drug developers, and individuals affected by C9ORF72-FTD/ALS to evaluate how collaborative efforts across the FTD-ALS disease spectrum might break down existing disease silos. Presentations and discussions covered recent discoveries in C9ORF72-FTD/ALS disease mechanisms, availability of disease biomarkers and recent advances in therapeutic development, and clinical trial design for prevention and treatment for individuals affected by C9ORF72-FTD/ALS and asymptomatic pathological expansion carriers.

View Article and Find Full Text PDF

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that affects motor neurons, causing progressive muscle weakness and respiratory failure. The presence of an expanded hexanucleotide repeat in chromosome 9 open reading frame 72 (C9ORF72) is the most frequent mutation causing familial ALS and frontotemporal dementia (FTD). To determine if suppressing expression of C9ORF72 gene products can reduce toxicity, we designed a set of artificial microRNAs (amiRNA) targeting the human C9ORF72 gene.

View Article and Find Full Text PDF

C9orf72 repeat expansions are the most common genetic cause of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). Poly(GR) proteins are toxic to neurons by forming cytoplasmic inclusions that sequester RNA-binding proteins including stress granule (SG) proteins. However, little is known of the factors governing poly(GR) inclusion formation.

View Article and Find Full Text PDF
Article Synopsis
  • - Abnormal expansions of the GGGGCC repeat sequence in noncoding regions are linked to familial amyotrophic lateral sclerosis and frontotemporal dementia, known as C9-ALS/FTD.
  • - Dipeptide repeat proteins (DPRs) from this expansion play a key role in disease progression, and the study investigates the regulatory effects of RNA-binding proteins (RBPs) on RAN translation related to these repeats.
  • - The research finds that the RBP FUS can suppress RAN translation and neurodegeneration by directly binding to the GGGGCC repeat RNA and influencing its G-quadruplex structure, offering potential therapeutic avenues for C9-ALS/FTD and similar diseases. *
View Article and Find Full Text PDF
Article Synopsis
  • TDP-43 protein aggregation is linked to conditions like amyotrophic lateral sclerosis and frontotemporal lobar degeneration, yet no effective treatments exist.
  • Researchers tested 15 TDP-43 peptide antigens to find safe, immunogenic targets for antibody therapy and identified several promising candidates, although one combination caused severe side effects in mice.
  • Immunization with a specific C-terminal peptide reduced neuroaxonal damage markers in mice, showing some potential benefits despite not preventing overall disease progression.
View Article and Find Full Text PDF

While motor and cortical neurons are affected in amyotrophic lateral sclerosis and frontotemporal dementia (ALS/FTD), it remains largely unknown if and how non-neuronal cells induce or exacerbate neuronal damage. We differentiated ALS/FTD patient-derived induced pluripotent stem cells into microglia (iPSC-MG) and examined their intrinsic phenotypes. Similar to iPSC motor neurons, ALS/FTD iPSC-MG mono-cultures form GC repeat RNA foci, exhibit reduced C9orf72 protein levels, and generate dipeptide repeat proteins.

View Article and Find Full Text PDF

Repeat expansions in the gene are the most common genetic cause of amyotrophic lateral sclerosis and familial frontotemporal dementia (ALS/FTD). To identify molecular defects that take place in the dorsolateral frontal cortex of patients with ALS/FTD, we compared healthy controls with ALS/FTD donor samples staged based on the levels of cortical phosphorylated TAR DNA binding protein (pTDP-43), a neuropathological hallmark of disease progression. We identified distinct molecular changes in different cell types that take place during FTD development.

View Article and Find Full Text PDF

Hexanucleotide GC repeat expansions in the gene are the most common genetic cause of amyotrophic lateral sclerosis and frontotemporal dementia. Dipeptide repeat proteins (DPRs) generated by translation of repeat-containing RNAs show toxic effects in vivo as well as in vitro and are key targets for therapeutic intervention. We generated human antibodies that bind DPRs with high affinity and specificity.

View Article and Find Full Text PDF

A hexanucleotide repeat expansion in intron 1 of the gene is the most common genetic cause of amyotrophic lateral sclerosis and frontotemporal dementia, or c9ALS/FTD. The RNA transcribed from the expansion, r(GC), causes various pathologies, including intron retention, aberrant translation that produces toxic dipeptide repeat proteins (DPRs), and sequestration of RNA-binding proteins (RBPs) in RNA foci. Here, we describe a small molecule that potently and selectively interacts with r(GC) and mitigates disease pathologies in spinal neurons differentiated from c9ALS patient-derived induced pluripotent stem cells (iPSCs) and in two c9ALS/FTD mouse models.

View Article and Find Full Text PDF

Importance: Physical activity is associated with cognitive health, even in autosomal dominant forms of dementia. Higher physical activity is associated with slowed cognitive and functional declines over time in adults carrying autosomal dominant variants for frontotemporal lobar degeneration (FTLD), but whether axonal degeneration is a potential neuroprotective target of physical activity in individuals with FTLD is unknown.

Objective: To examine the association between physical activity and longitudinal neurofilament light chain (NfL) trajectories in individuals with autosomal dominant forms of FTLD.

View Article and Find Full Text PDF

A GGGGCC hexanucleotide repeat expansion (HRE) in the C9ORF72 gene is the most common genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), fatal neurodegenerative diseases with no cure or approved treatments that substantially slow disease progression or extend survival. Mechanistic underpinnings of neuronal death include C9ORF72 haploinsufficiency, sequestration of RNA-binding proteins in the nucleus, and production of dipeptide repeat proteins. Here, we used an adeno-associated viral vector system to deliver CRISPR/Cas9 gene-editing machineries to effectuate the removal of the HRE from the C9ORF72 genomic locus.

View Article and Find Full Text PDF